Merck, Y0002407, Brivaracetam CRS

General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. Compendial materials should be used for the purpose described in the appropriate monograph unless otherwise authorized by the National Competent Authority. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
e.g. pharmaceutical (small molecule)
Biochem/physiol Actions
Brivaracetam shows approximately 10 times greater potency than levetiracetam (Keppra)*; pIC50 at LBS = 7.0; inhibits audiogenic seizures in seizure-prone mice (ED50 = 14 μmol/kg) and is also effective in other animal models of epilepsy. Brivaracetam is used as an anticonvulsant (antiepileptic) for seizure treatment.
Orally active levetiracetam analog with higher synaptic vesicle protein 2A (SV2A) affinity and >10 times greater in vivo antiseizure efficay.
Packaging
Unit quantity: 160mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.